Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray
Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?
Takeda indicates to analysts that it is warming to idea of buying Shire, but do Pfizer or Amgen make greater sense to acquire the rare disease specialist?